Taken together, these histomorphological features of HER2 amplified UBC—frequent micropapillary architecture, morphological heterogeneity and marked tumor-associated chronic inflammation—allow pathologists to better identify this clinically important, particularly aggressive subset of UBC [12] and herewith to contribute to enhanced survival prediction and preselection for potential anti-HER2 therapies in the future. The gene discussed is ERBB2; the disease is neoplasm.